Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy for High Risk DLBCL
NCT02636322Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2016
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2016; status: completed.
02
Drugs
ibrutiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02636322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636322.